AstraZeneca Pharmaceuticals LP
2751 articles about AstraZeneca Pharmaceuticals LP
-
Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
9/16/2022
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for Beyfortus® for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants during their first RSV season.
-
AstraZeneca's rare disease subsidiary Alexion posted positive late-stage results from a potential complementary treatment for paroxysmal nocturnal hemoglobinuria.
-
It was a busy weekend at ESMO 2022 with Merck, Astellas, Seagen, Regeneron, AstraZeneca and GRAIL all presenting data from their various cancer programs.
-
AstraZeneca presented data showing Imfinzi and Tagrisso boosted survival chances for patients in different forms of lung cancer at ESMO on Monday.
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
9/11/2022
Detailed positive results from an interim analysis of the DESTINY-Lung02 Phase II trial showed ENHERTU® demonstrated clinically meaningful tumor responses in previously-treated patients with HER2-mutant unresectable and/or metastatic non-squamous non-small cell lung cancer.
-
IMFINZI® (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy
9/11/2022
Updated results after approximately four years of follow-up of the POSEIDON Phase III trial showed a limited course of tremelimumab when added to AstraZeneca’s IMFINZI® plus four cycles of chemotherapy demonstrated a sustained improvement in overall survival compared to chemotherapy alone in the 1st-line treatment of patients with Stage IV non-small cell lung cancer.
-
TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
9/11/2022
Updated results from the pivotal ADAURA Phase III trial showed that AstraZeneca’s TAGRISSO® demonstrated a sustained, clinically meaningful improvement in disease-free survival compared to placebo in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.
-
An AstraZeneca/Merck combination showed mostly positive ovarian cancer data, Adaptimmune posted a strong ORR in solid tumors and BioNTech revealed data from a CAR-T cell therapy.
-
Preliminary findings from the NEURO-TTRansform trial show Ionis’ and AstraZeneca’s eplontersen is potentially a safe and effective treatment for patients with amyloidosis.
-
The FDA approved AstraZeneca’s Imfinzi plus with gemcitabine-cisplatin chemotherapy as the first immunotherapy for adult patients with locally advanced or metastatic biliary tract cancer.
-
IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer
9/5/2022
AstraZeneca’s IMFINZI® has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer in combination with chemotherapy.
-
A High Court judge in London granted AstraZeneca an injunction, temporarily blocking a former executive from joining rival pharma GSK.
-
AstraZeneca reported a pre-specified pooled analysis from its Phase III trial of the diabetes drug Farxiga in patients with heart failure.
-
FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
8/27/2022
Detailed results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA® significantly reduced the composite of cardiovascular death or worsening heart failure in patients with HF and mildly reduced or preserved ejection fraction, compared to placebo.
-
AstraZeneca announced a series of wins in Japan with regulatory approvals for Tagrisso, Ultomiris and Lynparza, to treat non-small cell lung cancer, myasthenia gravis and breast cancer, respectively.
-
LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
8/25/2022
AstraZeneca and Merck, known as MSD outside of the United States and Canada, announced that LYNPARZA has been approved by the Japan Pharmaceuticals and Medical Devices Agency for the adjuvant treatment for patients with BRCA-mutated, human epidermal growth factor receptor 2 -negative high recurrent risk breast cancer.
-
In an interview with Reuters, AstraZeneca CEO Pascal Soriot said Tuesday that he isn't sure if the company will continue developing vaccines. He also hinted at potential M&A action.
-
The FDA is busy accepting drug applications, granting specialty designations and approving drugs for market. Here's a look at this week's FDA activity.
-
Weeks after AstraZeneca and Daiichi Sankyo were able to move the bar in the treatment of metastatic breast cancer with Enhertu, Gilead is answering that challenge with Trodelvy.
-
AstraZeneca and Daiichi Sankyo’s Enhertu Racks up Another Clinical Win in Breast Cancer (Updated)
8/15/2022
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved by the FDA as the first HER2-directed medicine for the treatment of patients with HER2-mutant metastatic NSCLC.